For comparison, data from the “Fight Retinal Blindness!” registry, which followed AMD patients receiving intravitreal anti-VEGF injections, suggest an estimated 10-year rate of SMH of 4.4% of patients [1]. The gene discussed is VEGFA; the disease is age-related macular degeneration.